Oncology Research : Innovative New Anti-Cancer Drugs
PeLeMed is driven to rapidly design and develop new cancer therapies that address unmet medical needs and
help the patients who are refractory to conventional anti-cancer drugs that have not fully met their medical needs.
Discovery and Development of Innovative Anti-Cancer Drugs
PLM-102 : 3rd Generation FLT3 inhibitor targeting acquired resistant mutants (FLT3-ITD/F691L and FLT3-ITD/ D835Y) for Acute Myeloid Leukemia (AML)
- Pico-molar level binding affinities and anti-proliferative activities at all FLT3 mutants and corresponding Ba/F3-FLT3-ITD and -TKD cell lines
- High selectivity profile for FLT3 and its mutants in 468 kinase panel assay
- Selective and potent anti-AML activities in mutant FLT3 driving AML cell lines (Hematological cancer panel)
- Potent in vivo anti-cancer efficacy against FLT3-ITD/F691L and FLT3-ITD/D835Y mutants by oral administration (current unmet medical needs).
- Low toxicity profile in repeated toxicity study (blood cells, kidney and liver, etc)
Anti-viral Research : Innovative New Anti-Hepatitis B Virus Drugs
PeLeMed is driven to develop new anti-viral therapies targeting nucleocapsid and NTCP aiming at functional cure of chronic HBV infected patients who are in the risk of relapse after drug discontinuation.
Discovery and Development of Anti-HBV Drugs for Functional Cure
PLM-401, 402 : Potent Anti-HBV Drugs Targeting Nucleocapsid assembly
- Potent suppressive effects( or Powerful inhibitory effect )of the capsid assembly as class 1 modulators
- Highly synergistic effect in lowering serum HBV DNA levels in combination with Tenofovir
- Effective reduction of cccDNA levels from in vivo study using a humanized liver mouse model (PXB)
